8 results on '"Jun-ichi Saitoh"'
Search Results
2. Definitive Carbon-Ion Radiation Therapy for Locally Advanced Sinonasal Malignant Tumors: Subgroup Analysis of a Multicenter Study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS)
- Author
-
Hiroaki Suefuji, Tadashi Kamada, Hiroaki Ikawa, Kenji Nemoto, Yusuke Demizu, Yoshiyuki Shioyama, Hiroshi Tsuji, Tomoaki Okimoto, Masashi Koto, Tatsuya Ohno, Takashi Nakano, and Jun-ichi Saitoh
- Subjects
Nasal cavity ,Male ,Organs at Risk ,Cancer Research ,medicine.medical_treatment ,Gastroenterology ,Radiation Tolerance ,030218 nuclear medicine & medical imaging ,0302 clinical medicine ,Esthesioneuroblastoma ,Ethmoid Sinus ,Japan ,Melanoma ,Aged, 80 and over ,Radiation ,Mucosal melanoma ,Middle Aged ,Salivary Gland Neoplasms ,Carcinoma, Adenoid Cystic ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Adenocarcinoma ,Female ,Paranasal Sinus Neoplasms ,Adult ,medicine.medical_specialty ,Sphenoid Sinus ,Adenoid cystic carcinoma ,Maxillary Sinus Neoplasms ,Nose Neoplasms ,Esthesioneuroblastoma, Olfactory ,Heavy Ion Radiotherapy ,03 medical and health sciences ,Young Adult ,Internal medicine ,medicine ,Carcinoma ,Humans ,Radiology, Nuclear Medicine and imaging ,Aged ,Retrospective Studies ,Olfactory Neuroblastoma ,business.industry ,medicine.disease ,Radiation therapy ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Purpose To evaluate the safety and efficacy of carbon-ion radiation therapy (C-ion RT) for locally advanced sinonasal malignant tumors in a multicenter retrospective study (J-CROS 1402 HN). Methods and Materials Clinical data were collected for patients who had sinonasal malignant tumors of stage N0-1M0 and received C-ion RT at 4 institutions in Japan between November 2003 and December 2014. Of the 458 patients, 393 had naive tumors and 65 had recurrent tumors. The tumors were located in the nasal cavity (n = 263), maxillary sinus (n = 109), ethmoid sinus (n = 71), and other locations (n = 15). The histologic types were mucosal melanoma (n = 221, 48%), adenoid cystic carcinoma (n = 122, 27%), squamous cell carcinoma (n = 31, 7%), olfactory neuroblastoma (n = 30, 7%), adenocarcinoma (n = 21, 5%), and other types (n = 33, 7%). Of the 458 patients, 300 (66%) had T4 tumors. All patients received definitive C-ion RT. Results The median follow-up period was 25.2 months for all patients (range, 1.4-132.3 months). The 2-year overall survival and local control rates were 79.6% and 84.1%, respectively. As analyzed according to histology, the 2-year overall survival rate was 68.0% for mucosal melanoma, 96.8% for adenoid cystic carcinoma, 70.0% for squamous cell carcinoma, 96.7% for olfactory neuroblastoma, and 89.7% for adenocarcinoma. Regarding late toxicities, 17% of patients developed grade 3 and 4 toxicities, of which visual impairment was the most common. Conclusion The results of our multicenter study have demonstrated that C-ion RT can provide excellent clinical outcomes with acceptable late toxicities in patients who have locally advanced sinonasal malignant tumors.
- Published
- 2018
3. A Multicenter Study of Carbon-Ion Radiation Therapy for Head and Neck Adenocarcinoma
- Author
-
Yusuke Demizu, Hiroaki Suefuji, Kenji Nemoto, Takashi Nakano, Masashi Koto, Yoshiyuki Shioyama, Tomoaki Okimoto, Tatsuya Ohno, Jun-ichi Saitoh, Hiroshi Tsuji, and Tadashi Kamada
- Subjects
Male ,Organs at Risk ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Heavy Ion Radiotherapy ,Adenocarcinoma ,Gastroenterology ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective cohort study ,Head and neck ,Radiation Injuries ,Sinus (anatomy) ,Retrospective Studies ,Radiation ,business.industry ,Pharynx ,Middle Aged ,medicine.disease ,Surgery ,Radiation therapy ,Survival Rate ,Paranasal sinuses ,medicine.anatomical_structure ,Treatment Outcome ,Oncology ,Multicenter study ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Female ,Dose Fractionation, Radiation ,business ,Relative Biological Effectiveness - Abstract
Purpose Head and neck (HN) adenocarcinoma is rare, and to date, there have been no reports of prospective studies. We retrospectively evaluated the efficacy and safety of carbon-ion radiation therapy (C-ion RT) for HN adenocarcinoma in institutions in Japan. Methods and Materials HN adenocarcinoma patients with N0M0 or N1M0 disease who were treated with C-ion RT at institutions in Japan between November 2003 and December 2014 were analyzed retrospectively. We enrolled 47 patients (30 male and 17 female patients; median age, 60 years) with HN adenocarcinoma. Results Primary sites included the nasal and paranasal sinus in 21 patients, orbit in 11, salivary grand in 7, oral cavity and pharynx in 6, and acoustic organ in 2. Thirty-two patients had T4 tumors, 6 had T3, and 6 had T2. Forty-five patients received a diagnosis of N0 disease, whereas 2 had N1 disease. The median total dose of C-ion RT and the number of fractions were 64.0 Gy (relative biological effectiveness) and 16 fractions, respectively. The median follow-up period was 51 months (range, 6-118 months). The 2- and 5-year overall survival rates were 87.9% and 60.4%, respectively, and the 2- and 5-year local control rates were 83.3% and 79.3%, respectively. Multivariate analysis showed that operability (patients with operable tumors) ( P =.045) and fractionation (16 fractions) ( P =.010) were significant independent prognostic factors for better overall survival. No grade 5 late morbidities were observed. Grade 4 late morbidities were observed in 4 patients, and all of these grade 4 morbidities were visual impairments. All 4 patients with grade 4 visual impairment had T4 tumors in the nasopharynx or paranasal sinuses, which implied inoperable tumors with orbital or brain invasion. Conclusions C-ion RT resulted in excellent local control. C-ion RT could become a curative treatment option for HN adenocarcinoma with acceptable toxicities.
- Published
- 2016
4. Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN)
- Author
-
Yusuke Demizu, Jun-ichi Saitoh, Masashi Koto, Kenji Nemoto, Takashi Nakano, Yoshiyuki Shioyama, Takashi Daimon, Tomoaki Okimoto, Tatsuya Ohno, Hiroshi Tsuji, Nor Shazrina Sulaiman, Tadashi Kamada, and Hiroaki Suefuji
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Heavy Ion Radiotherapy ,Gastroenterology ,Disease-Free Survival ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Risk Factors ,Internal medicine ,Carcinoma ,Prevalence ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Progression-free survival ,Melanoma ,Imidazole carboxamide ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Radiation ,Mucous Membrane ,business.industry ,Head and neck cancer ,Mucosal melanoma ,Dose fractionation ,Middle Aged ,medicine.disease ,Surgery ,Radiation therapy ,Paranasal sinuses ,medicine.anatomical_structure ,Treatment Outcome ,Oncology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Purpose To evaluate the efficacy and safety of carbon-ion radiation therapy (RT) for mucosal melanoma of the head and neck (MMHN) in the Japan Carbon-Ion Radiation Oncology Study Group study. Methods and Materials Patients with MMHN with N0-1M0 status who were treated with carbon-ion RT at 4 institutions in Japan between November 2003 and December 2014 were analyzed retrospectively. Two hundred sixty patients (male, 111; female, 149; median age, 68 years) with histologically proven MMHN were enrolled. Results Primary sites included the nasal cavity in 178 patients, paranasal sinuses in 43, oral cavity in 27, and pharynx in 12. Eighty-six patients had T3 tumors, 147 had T4a tumors, and 27 had T4b tumors. Two hundred fifty-one patients were diagnosed with N0 disease, and 9 with N1 disease. The median total dose and number of fractions were 57.6 Gy RBE (relative biological effectiveness) and 16, respectively. Chemotherapy including dimethyl traizeno imidazole carboxamide was used concurrently in 129 patients. The median follow-up duration was 22 months (range, 1-132 months). The 2-year overall survival and local control rates were 69.4% and 83.9%, respectively. Multivariate analysis showed that gross tumor volume and concurrent chemotherapy were significant prognostic factors for overall survival. Grade 3 and grade 4 late morbidities were observed in 27 and 7 patients (5 developed ipsilateral blindness, 1 mucosal ulcer, and 1 second malignant disease in the irradiated volume), respectively. No patients developed grade 5 late morbidities. Conclusion Carbon-ion RT is a promising treatment option for MMHN.
- Published
- 2016
5. Verification of Dose Distribution in Carbon Ion Radiation Therapy for Stage I Lung Cancer
- Author
-
Katsuyuki Shirai, Tatsuya Ohno, Yoshiki Kubota, Shin-ei Noda, Jun-ichi Saitoh, Makoto Sakai, Takashi Nakano, Takanori Abe, and Daisuke Irie
- Subjects
Male ,Cancer Research ,Lung Neoplasms ,medicine.medical_treatment ,Movement ,Planning target volume ,Heavy Ion Radiotherapy ,Dose distribution ,Bone and Bones ,Patient Positioning ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Structure matching ,Aged ,Radiation ,Stage I Lung Cancer ,Receiver operating characteristic ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Respiration ,Carbon Ion Radiation Therapy ,Tumor Burden ,Radiation therapy ,Oncology ,ROC Curve ,030220 oncology & carcinogenesis ,Area Under Curve ,Female ,Dose Fractionation, Radiation ,Anatomic Landmarks ,Radiotherapy, Conformal ,Nuclear medicine ,business ,Wall thickness ,Tomography, X-Ray Computed - Abstract
Purpose To evaluate robustness of dose distribution of carbon-ion radiation therapy (C-ion RT) in non-small cell lung cancer (NSCLC) and to identify factors affecting the dose distribution by simulated dose distribution. Methods and Materials Eighty irradiation fields for delivery of C-ion RT were analyzed in 20 patients with stage I NSCLC. Computed tomography images were obtained twice before treatment initiation. Simulated dose distribution was reconstructed on computed tomography for confirmation under the same settings as actual treatment with respiratory gating and bony structure matching. Dose-volume histogram parameters, such as %D95 (percentage of D95 relative to the prescribed dose), were calculated. Patients with any field for which the %D95 of gross tumor volume (GTV) was below 90% were classified as unacceptable for treatment, and the optimal target margin for such cases was examined. Results Five patients with a total of 8 fields (10% of total number of fields analyzed) were classified as unacceptable according to %D95 of GTV, although most patients showed no remarkable change in the dose-volume histogram parameters. Receiver operating characteristic curve analysis showed that tumor displacement and change in water-equivalent pathlength were significant predictive factors of unacceptable cases ( P P =.002, respectively). The main cause of degradation of the dose distribution was tumor displacement in 7 of the 8 unacceptable fields. A 6-mm planning target volume margin ensured a GTV %D95 of >90%, except in 1 extremely unacceptable field. Conclusions According to this simulation analysis of C-ion RT for stage I NSCLC, a few fields were reported as unacceptable and required resetting of body position and reconfirmation. In addition, tumor displacement and change in water-equivalent pathlength (bone shift and/or chest wall thickness) were identified as factors influencing the robustness of dose distribution. Such uncertainties should be regarded in planning.
- Published
- 2016
6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity
- Author
-
Koichi Harashima, Hideo Niibe, Yuko Nakayama, Takumi Yamamoto, Kazuto Ito, Kazuhiro Suzuki, Shin-ei Noda, Tetsuo Akimoto, Hideyuki Sakurai, Jun-ichi Saitoh, and Takashi Nakano
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Brachytherapy ,Effective dose (radiation) ,Prostate cancer ,Urethra ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiation Injuries ,Aged ,Aged, 80 and over ,Analysis of Variance ,Radiation ,medicine.diagnostic_test ,business.industry ,Dose fractionation ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,Iridium Radioisotopes ,Urination Disorders ,Combined Modality Therapy ,Acute toxicity ,High-Dose Rate Brachytherapy ,Surgery ,Radiation therapy ,Oncology ,Transrectal ultrasonography ,Feasibility Studies ,Radiology ,Dose Fractionation, Radiation ,business - Abstract
Purpose: Several investigations have revealed that the α/β ratio for prostate cancer is atypically low, and that hypofractionation or high-dose-rate (HDR) brachytherapy regimens using appropriate radiation doses may be expected to yield tumor control and late sequelae rates that are better or at least as favorable as those achieved with conventional radiation therapy. In this setting, we attempted treating localized prostate cancer patients with HDR brachytherapy combined with hypofractionated external beam radiation therapy (EBRT). The purpose of this study was to evaluate the feasibility of using this approach, with special emphasis on the relationship between the severity of acute genitourinary (GU) toxicity and the urethral dose calculated from the dose–volume histogram (DVH) of HDR brachytherapy. Methods and Materials: Between September 2000 and December 2003, 70 patients with localized prostate cancer were treated by iridium-192 HDR brachytherapy combined with hypofractionated EBRT at the Gunma University Hospital. Hypofractionated EBRT was administered in fraction doses of 3 Gy, three times per week; a total dose of 51 Gy was delivered to the prostate gland and the seminal vesicles using the four-field technique. No elective pelvic irradiation was performed. After the completion of EBRT, all the patients additionally received transrectal ultrasonography (TRUS)-guided HDR brachytherapy. The fraction size and the number of fractions in HDR brachytherapy were prospectively changed, whereas the total radiation dose for EBRT was fixed at 51 Gy. The fractionation in HDR brachytherapy was as follows: 5 Gy × 5, 7 Gy × 3, 9 Gy × 2, administered twice per day, although the biologic effective dose (BED) for HDR brachytherapy combined with EBRT, assuming that the α/β ratio is 3, was almost equal to 138 in each fractionation group. The planning target volume was defined as the prostate gland with 5-mm margin all around, and the planning was conducted based on computed tomography images. The number of patients in each fractionation group was as follows: 13 in the 5-Gy group; 19 in the 7-Gy group, and 38 in the 9-Gy group. The tumor stage was T1 in 10 patients, T2 in 36 patients, and T3 in 24 patients. The Gleason score was 2–6 in 11 patients, 7 in 34 patients, and 8–10 in 25 patients. Androgen ablation was performed in all the patients. The median follow-up duration was 14 months (range 3–42 months). The toxicities were graded based on the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer toxicity criteria. Results: The main symptoms of acute GU toxicity were dysuria and increase in urinary frequency or nocturia. The grade distribution of acute GU toxicity in the patients was as follows: Grade 0–1, 39 patients (56%), and Grade 2–4, 31 patients (44%). One patient who developed acute urinary obstruction was classified as having Grade 4 toxicity. Comparison of the distribution of the grade of acute GU toxicity among the different fractionation groups revealed no statistically significant differences among the groups. The urethral dose in HDR brachytherapy was evaluated using the following DVH parameters: V30 (percentage of the urethral volume receiving 30% of the prescribed radiation dose), V80, V90, V100, V110, V120, V130, and V150. The V30–110 values in the patients with Grade 2–4 acute GU toxicity were significantly higher than those in patients with Grade 0–1 toxicity. On the other hand, there were no significant differences in the V120–150 values between patients with Grade 0–1 and Grade 2–4 toxicity. Regarding the influence of the number of needles implanted for the radiation therapy, patients with 11 needles or less showed a significantly higher incidence of Grade 2–4 acute GU toxicity compared with those with 12 needles or more (p Conclusions: It was concluded that HDR brachytherapy combined with hypofractionated EBRT is feasible for localized prostate cancer when considered from the viewpoint of acute toxicity. Increase in the fraction dose or reduction in the number of fractions in HDR brachytherapy did not affect the severity of acute GU toxicity, and the volume of urethra receiving an equal or lower radiation dose than the prescribed dose was more closely associated with the grade severity of acute GU toxicity than that receiving a higher than the prescribed dose.
- Published
- 2004
7. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma
- Author
-
Norio Mitsuhashi, Mitsuhiro Takahashi, Jun-ichi Saitoh, Masatoshi Hasegawa, Yoshizumi Kitamoto, Hideyuki Sakurai, Hitoshi Ishikawa, Masanobu Nakajima, Norihiro Masuda, and Takashi Nakano
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Combination therapy ,FIGO Stage IIIB ,medicine.medical_treatment ,Brachytherapy ,Uterine Cervical Neoplasms ,Disease-Free Survival ,Statistics, Nonparametric ,Metastasis ,Internal medicine ,Proto-Oncogene Proteins ,Carcinoma ,medicine ,Biomarkers, Tumor ,Humans ,Radiology, Nuclear Medicine and imaging ,Cervix ,Papillomaviridae ,Aged ,bcl-2-Associated X Protein ,Aged, 80 and over ,Radiation ,business.industry ,HPV infection ,Middle Aged ,medicine.disease ,Hypoxia-Inducible Factor 1, alpha Subunit ,Cell Hypoxia ,Radiation therapy ,medicine.anatomical_structure ,Proto-Oncogene Proteins c-bcl-2 ,Carcinoma, Squamous Cell ,Female ,Tumor Suppressor Protein p53 ,business ,Transcription Factors - Abstract
Hypoxia-inducible factor-1alpha (HIF-1alpha) is an intrinsic marker of tumor hypoxia. It has been considered that the hypoxic status reduces radiosensitivity, but the role of HIF-1alpha in advanced cervical carcinoma is still unclear. The objective of this study was to clarify the impact of HIF-1alpha, human papillomavirus (HPV), and other molecular factors, such as p53, bax, bcl-2, and their correlations on the outcome of patients with Stage IIIB cervical carcinoma in radiation therapy.We analyzed 38 patients with FIGO Stage IIIB squamous cell carcinoma of the cervix treated with radiation therapy alone. All patients received the combination therapy of external beam irradiation and low-dose-rate intracavity brachytherapy. The tumor expressions of HIF-1alpha, p53, bax, and bcl-2 were examined by immunohistochemical staining of the pretreatment paraffin embedded specimens. HPV infection was also detected by polymerase chain reaction. The effects of these parameters on clinical outcomes were analyzed by univariate analysis.Of 38 patients, high expression of HIF-1alpha, p53, bax, and bcl-2 were seen in 17 (45%), 22 (58%), 15 (39%), and 15 (39%) patients, respectively, and 28 patients (74%) showed positive infection with HPV. There was a significant positive correlation between high HIF-1alpha expression and disease recurrence (p0.05). Furthermore, HIF-1alpha had a significant correlation with the recurrence-free survival rate (p = 0.04). No statistical correlation was noted between high HIF-1alpha expression and the local control rate (p = 0.17), whereas the HIF-1alpha status predicted distant metastasis with strong significance (p = 0.03). Conversely, other factors demonstrated no impact on the clinical outcome.The present results suggest that HIF-1alpha is an important prognostic factor, especially for predicting future metastasis after radiation therapy for patients with Stage IIIB squamous cell carcinoma of the cervix.
- Published
- 2003
8. Correlations between in vivo tumor weight, oxygen pressure, 31P NMR spectroscopy, hypoxic microenvironment marking by beta-D-iodinated azomycin galactopyranoside (beta-D-IAZGP), and radiation sensitivity
- Author
-
Tetsuo Akimoto, Hideyuki Sakurai, Hitoshi Ishikawa, Takashi Nakano, Yoshiyuki Suzuki, Masatoshi Hasegawa, Hiroyuki Muramatsu, Jun-ichi Saitoh, Yoshizumi Kitamoto, and Norio Mitsuhashi
- Subjects
Male ,Cancer Research ,Biodistribution ,Magnetic Resonance Spectroscopy ,Partial Pressure ,chemistry.chemical_element ,Mammary Neoplasms, Animal ,Oxygen ,Radiation Tolerance ,Phosphocreatine ,chemistry.chemical_compound ,Mice ,Radiation sensitivity ,In vivo ,Medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,Radiosensitivity ,Clonogenic assay ,Mice, Inbred C3H ,Radiation ,business.industry ,Monosaccharides ,Organ Size ,Tumor Oxygenation ,Molecular biology ,Cell Hypoxia ,Oncology ,chemistry ,Nitroimidazoles ,Female ,business ,Nuclear medicine ,Biomarkers - Abstract
Purpose: The purpose of this study is to evaluate the amount of hypoxic fraction in a rodent tumor by means of polarographic oxygen electrode, phosphorus-31 magnetic resonance spectroscopy ( 31 P-MRS), and a newly synthesized hypoxic marker, β-D-iodinated azomycin galactopyranoside (β-D-IAZGP). We also investigated the radiosensitivity for tumors of different weights. Methods and Materials: Murine mammary carcinoma cells, FM3A, were subcutaneously implanted into the back of 5-week-old male C3H/He mice. β-D-IAZGP radiolabeled with 123 I or with 125 I was injected intravenously into tumor-bearing mice, and marker distribution was measured by nuclear medicine procedures. Radiosensitivity of the tumor was measured by the in vivo / in vitro clonogenic assay. Tumor oxygenation status was also measured directly by polarographic oxygen electrodes and indirectly estimated from 31 P-MR spectra. Results: Higher accumulation of 123 I-β-D-IAZGP was observed in the tumors than in normal tissues at 24 h after administration. As to biodistribution of 125 I-β-D-IAZGP, the tumor/blood ratio varied widely, but correlated significantly with tumor weight. Mean oxygen pressure (pO 2 ) values and ratios of nucleoside triphosphate β to inorganic phosphate (β-ATP/Pi) and of phosphocreatine to inorganic phosphate (PCr/Pi) decreased significantly with the increase in tumor volume. As tumor volume increased, the surviving fraction of cells from tumors irradiated in vivo increased significantly. Conclusions: The increase in tumor volume was significantly correlated with a reduction in mean pO 2 , a decrease in the ratios of β-ATP/Pi or PCr/Pi, an increase in uptake of β-D-IAZGP, and an increase in radioresistance. Because the uptake of β-D-IAZGP can be measured noninvasively by nuclear medicine techniques, it could be clinically useful for monitoring hypoxia in human tumors.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.